New research shows how some bacteria manage to evade a widely used antibiotic by
removing it from their protein factories.
The widespread use of
antibiotics over the past decades has led to the emergence of resistant
bacteria. Since their discovery in the 1930s, antibiotics have been overused in
human medicine and in industrial farms as food supplements to promote animal
growth. A shocking 80% of antibiotics produced in the USA are used in farms, despite
warnings from the World Health Organization of the danger this poses to public
health. Antibiotic resistant bacteria can spread from animals to humans through
meat, water and soil contamination. A few countries, like European Union member
countries and South Korea, have recently restricted the use of antibiotics for
clinical purposes, but the number of resistant bacteria strains continues to rise
at an alarming rate worldwide, and new antibiotics are needed to gain ground against
bacteria.
Understanding the molecular
details of antibiotic resistance is crucial for the design of effective drugs. Now, two independent studies describe how bacteria evade tetracyclines, a family of antibiotics
that act against a broad range of bacteria involved in diseases such as pneumonia,
syphilis, cholera and even some strains of the deadly MRSA superbug.
An attack on the bacterial protein
factories
Like many other antibiotics,
tetracycline drugs work by targeting the bacteria’s protein factories- the ribosomes-
and blocking protein production. This doesn’t kill the bacteria, but it stops
them from multiplying, which buys the immune system critical time to fight the
infection.
Bacteria have many strategies
to escape tetracycline drugs, but the most common is the use of specialised
proteins that remove the drug from its target, a process called ribosome
protection. To understand how this works, Joachim Frank and colleagues at
Columbia University determined the 3D structure of one such protein - Tet(O) - bound
to ribosomes using cryo-electron microcopy, a technique where samples are
frozen quickly and then analysed with a high-power microscope.
Previous
work by the team suggested that Tet(O) acts indirectly by attaching to
ribosomes and forcing them to change shape so that tetracycline molecules can't
stick to them. In a new study published in Nature Communications, Frank’s team shows not only how Tet(O) pulls
this off, but also that, unexpectedly, Tet(O) pushes tetracycline molecules away from
ribosomes. This gives bacteria double protection against antibiotics.
MRSA bacteria magnified with a scanning electron microscope. (Credit: Wikipedia Commons) |
A step towards new antibiotics
With
their detailed 3D structure, the researchers could predict the attachment sites
between Tet(O) and the ribosome, which in theory should be essential for
ribosomal protection. To test this, they put Tet(O) proteins with missing bits into
bacteria, and checked whether they lost the resistance to tetracycline.
Why
is this important? These Tet(O)-ribosome binding regions are very likely to change
and adapt to the new generation of tetracycline antibiotics that are currently
our last defense against some strains of MRSA. With these molecular details
scientists can make a good guess where new resistances might appear, and then “an
antibiotic might be designed to have affinity to multiple sites near or around
the Tet(O)-ribosome binding site” says Frank.
Daniel Wilson’s team at the
University of Munich reports similar findings in a study published recently in PNAS, looking at the interaction
of ribosomes with Tet(O)’s sister protein Tet(M). Wilson explains "Our main
finding is that the Tet(M) protein directly enters into the tetracycline
binding site to dislodge the drug from the ribosome".
Antibiotic resistance: how grim is the future?
Unfortunately, in the race
between bacteria and men, bacteria have the upper hand. The genes carrying antibiotic
resistance, such as the tet genes
encoding for Tet(O) and Tet(M) proteins, can quickly spread between bacteria in
mobile DNA elements. To make matters worse, these genes can mutate and create new
resistances much faster than effective antibiotics can be made and tested in
clinical trials. “New antibiotics are urgently needed to fight the growing and
threatening development of multi-resistant bacteria strains” says Knud
Nierhaus, an expert on ribosome structure and antibiotic resistance from the Max
Plank Institute for Molecular Genetics in Berlin.
What is the best strategy
to tackle antibiotic resistance in the future? It is estimated that China uses
in its industrial farms about four times the total amount of antibiotics used in
the USA, and a new study identified around 150 new antibiotic resistant genes
in manure samples from only three Chinese farms. “The most dangerous development, with unpredictable
results on the human race, is the indiscriminate use of existing antibiotics,
including antibiotics in livestock entering the food chain” says Frank “Regulation
of agriculture should be a major part of the strategy, along with targeted drug
development.”
References:
Li, W., Atkinson, G., Thakor, N., Allas, U., Lu, C., Chan, K., Tenson, T., Schulten, K., Wilson, K., Hauryliuk, V., & Frank, J. (2013). Mechanism of tetracycline resistance by ribosomal protection protein Tet(O) Nature Communications, 4 DOI: 10.1038/ncomms2470
Donhofer, A., Franckenberg, S., Wickles, S., Berninghausen, O., Beckmann, R., & Wilson, D. (2012). Structural basis for TetM-mediated tetracycline resistance Proceedings of the National Academy of Sciences, 109 (42), 16900-16905 DOI: 10.1073/pnas.1208037109
This article was published in the Munich Eye on 12-02-13. You can read it here.
This article was published in the Munich Eye on 12-02-13. You can read it here.
No comments:
Post a Comment